Heartland virus (HRTV) is a pathogenic phlebovirus related to the severe fever with thrombocytopenia syndrome virus (SFTSV), another phlebovirus causing life-threatening disease in humans. Previous findings have suggested that SFTSV can antagonize the host interferon (IFN) system via viral nonstructural protein (NSs)-mediated sequestration of antiviral signaling proteins into NSs-induced inclusion bodies. However, whether and how HRTV counteracts the host innate immunity is unknown. Here, we report that HRTV NSs (HNSs) also antagonizes IFN and cytokine induction and bolsters viral replication, although no noticeable inclusion body formation was observed in HNSs-expressing cells. Furthermore, HNSs inhibited the virus-triggered activation of IFN-␤ promoter by specifically targeting the IFN-stimulated response element but not the NF-B response element. Consistently, HNSs blocked the phosphorylation and nuclear translocation of IFN regulatory factor 3 (IRF3, an IFN-stimulated response element-activating transcription factor). Reporter gene assays next showed that HNSs blockades the antiviral signaling mediated by RIG-I-like receptors likely at the level of TANK-binding kinase 1 (TBK1). Indeed, HNSs strongly interacts with TBK1 as indicated by confocal microscopy and pulldown analyses, and we also noted that the scaffold dimerization domain of TBK1 is required for the TBK1-HNSs interaction. Finally, pulldown assays demonstrated that HNSs expression dose-dependently diminishes a TBK1-IRF3 interaction, further explaining the mechanism for HNSs function. Collectively, these data suggest that HNSs, an antagonist of host innate immunity, interacts with TBK1 and thereby hinders the association of TBK1 with its substrate IRF3, thus blocking IRF3 activation and transcriptional induction of the cellular antiviral responses.
Heartland virus (HRTV) is a pathogenic phlebovirus related to the severe fever with thrombocytopenia syndrome virus (SFTSV), another phlebovirus causing life-threatening disease in humans. Previous findings have suggested that SFTSV can antagonize the host interferon (IFN) system via viral nonstructural protein (NSs)-mediated sequestration of antiviral signaling proteins into NSs-induced inclusion bodies. However, whether and how HRTV counteracts the host innate immunity is unknown. Here, we report that HRTV NSs (HNSs) also antagonizes IFN and cytokine induction and bolsters viral replication, although no noticeable inclusion body formation was observed
in HNSs-expressing cells. Furthermore, HNSs inhibited the virus-triggered activation of IFN-␤ promoter by specifically targeting the IFN-stimulated response element but not the NF-B response element. Consistently, HNSs blocked the phosphorylation and nuclear translocation of IFN regulatory factor 3 (IRF3, an IFN-stimulated response element-activating transcription factor). Reporter gene assays next showed that HNSs blockades the antiviral signaling mediated by RIG-I-like receptors likely at the level of TANK-binding kinase 1 (TBK1). Indeed, HNSs strongly interacts with TBK1 as indicated by confocal microscopy and pulldown analyses, and we also noted that the scaffold dimerization domain of TBK1 is required for the TBK1-HNSs interaction. Finally, pulldown assays demonstrated that HNSs expression dose-dependently diminishes a TBK1-IRF3 interaction, further explaining the mechanism for HNSs function. Collectively, these data suggest that HNSs, an antagonist of host innate immunity, interacts with TBK1 and thereby hinders the association of TBK1 with its substrate IRF3, thus blocking IRF3 activation and transcriptional induction of the cellular antiviral responses.
Heartland virus (HRTV) 3 is a novel phlebovirus (Phlebovirus genus, Phenuiviridae family, Bunyavirales order) associated with a severe febrile illness in humans (1) . The original cases of HRTV infections were reported in two Missouri farmers hospitalized with fever, leukopenia, and thrombocytopenia in 2009 (1) . Additional HRTV disease cases (including three fatalities) were subsequently identified in Missouri, Tennessee, and Oklahoma from 2009 to 2015 (2) (3) (4) . The Lone Star tick (Amblyomma americanum) has been implicated as a vector of the virus (5) ; some wild and domestic animals including white-tail deer, raccoons, horses, dogs, and opossums are likely the potential amplification hosts of HRTV (6) . A retrospective investigation of HRTV-neutralizing antibodies in the candidate vertebrate hosts further showed that HRTV is likely widespread in the central and eastern United States (7) . HRTV is genetically related to the severe fever with thrombocytopenia syndrome virus (SFTSV), also a highly pathogenic phlebovirus emerging in China and neighboring countries (8 -13) . The emergences of SFTSV, HRTV, and their recently discovered relatives, collectively termed the SFTSV/HRTV-group viruses, have raised new concerns in the public health worldwide (14 -16) . However, there is currently no vaccine or drug available against these emerging viruses.
Innate immunity, the first-line host defense against viral infections, is initiated with the recognition of pathogen-associated molecular patterns by pattern recognition receptors (PRRs) (17) (18) (19) . Retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs, the cytosolic RNA PRRs), RIG-I and MDA5, play pivotal roles in response to bunyavirus infections (20 -22) . Upon recognizing the RNA products of viral infections, RIG-I and MDA5 are activated and subsequently interact with the common adaptor MAVS (also known as VISA, CARDIF, and IPS-1) on mitochondrial membranes (23) (24) (25) (26) , leading to the formation of antiviral MAVS polymers (27) . MAVS recruits further members of the signal transduction cascade, including the crucial kinases, such as TBK1/IKK⑀ and IKK␣/IKK␤, which direct the activation of the transcription factors IRF3 and NF-B, respectively (18, 28) . Activated transcription factors are then translocalized in nuclei to induce the expression of interferons (IFNs) and other cytokines, eventually orchestrating the innate and adaptive antiviral immune responses (29 -32) .
The efficacy of viral subversion of host immune defense is pivotal for viral infectivity and pathogenicity (33, 34) . The understanding of the viral factor(s) governing viral infectivity and pathogenicity is urgently required for the development of antiviral therapies and safe vaccines. As phleboviruses, SFTSV/ HRTV-group viruses contain a tri-segmented negative-sense RNA genome. The large (L) and medium (M) segments of the genome encode the RNA-dependent RNA polymerase and the glycoprotein (GP) precursor, respectively, and the small segment (S) encodes the nucleoprotein (NP) and the nonstructural protein (NSs) by an ambisense coding strategy. Previous studies by us and others have shown that SFTSV antagonizes IFN induction by NSs hijacking of signaling molecules including a TBK1-IRF3 complex into NSs-induced inclusion bodies (IBs) (35) (36) (37) ; however, whether and how HRTV can interfere with the host innate immune response is unknown.
In this study we showed that HRTV NSs (HNSs) also functions as a robust antagonist of host innate immunity, thus promoting viral replication. Although its expression appears not to induce noticeable IB formation in multiple cell lines we tested, HNSs can inhibit RLR-mediated antiviral signaling and virusinfection-triggered IFN and inflammatory cytokine expression. Mechanistically, we found that HNSs disrupt the IFN-stimulated response element (ISRE) activation by interfering with IRF3 phosphorylation and nuclear accumulation; furthermore, HNSs interact with TBK1 and likely hinder TBK1-IRF3 association, thus disabling IRF3 activation and IFN and cytokine induction.
Results

HNSs exhibited a different subcellular localization from SFTSV NSs (SNSs)
SNSs is localized to SNSs self-induced IBs potentially with versatile roles (35) . To elucidate the function of HNSs, we first compared the subcellular localization of HNSs and SNSs. HEK293 cells transfected with plasmids expressing SNSs or HNSs were fixed to visualize the localization of the viral proteins by laser confocal microscopy after immunofluorescence assays (IFA). Consistent with our previous studies (35, 38) , SNSs remarkably induces the formation of cytoplasmic IBs where SNSs is located ( Fig. 1A) ; however, intriguingly, HNSs is located diffusely in cytoplasm rather than in any noticeable IBlike structures. The distinct subcellular localization of these NSs proteins could also be observed in other cell types including HepG2 (human hepatocyte), HUVEC (human umbilical vein endothelial cell), HeLa (human cervical cancer cell), HEK293T (a variant of HEK293, human kidney cell), Huh7.5 (human hepatocyte), Vero (green monkey kidney cell), and H9c2 (rat cardiac mytoblast) ( Fig. 1 , B-D, and data not shown).
HNSs inhibited viral infection-triggered activation of IFN-␤ promoter and expression of IFNB1 and RANTES, promoting viral replication
Previous studies by us and others have shown that SNSs is a robust antagonist of type I IFN induction (35) (36) (37) . To determine whether HNSs plays such a role, we examined the influence of HNSs expression on IFN-␤ promoter activation by viral infection with DLR assays. As shown in Fig. 2A , Sendai virus (SeV) infection strongly triggered IFN-␤ promoter activation, whereas this activation was significantly attenuated in the context of SNSs expression, consistent with the previous reports (35) (36) (37) . Interestingly, expression of HNSs, but not HRTV NP (HNP), also resulted in a remarkable suppression of SeV-triggered IFN-␤ promoter activation, comparable with that mediated by SNSs ( Fig. 2A, left and middle) . Meanwhile, the expression of these viral proteins in the DLR assays was also monitored by Western blotting (WB) analyses, and a representative result was presented on the right panel of Fig. 2A showing the comparable expression levels of the viral proteins. These data suggest that, like SNSs, HNSs can also act as a potent antagonist of IFN induction. 
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Furthermore, the effects of HNSs on virus-stimulated expression of IFNB1 and inflammatory cytokine gene RANTES were evaluated by real-time quantitative PCR analyses. As expected, HNSs significantly inhibited SeV-triggered expres-sion of IFNB1 and RANTES (Fig. 2B ), confirming the obstruction of the innate immune responses by HNSs.
Wu et al. (39) showed that SFTSV replication could be increased by the overexpression of SNSs. Given the capacity 
. HNSs inhibited virus-triggered activation of IFN-␤ promoter and expression of IFN-␤ and inflammatory cytokine genes, promoting viral replication.
A, HEK293 cells were cotransfected with the IFN-␤ promoter reporter plasmid and the Renilla luciferase control plasmid (pRL-TK) along with an empty control plasmid (Vector) or the plasmids encoding S-tagged HNP, HNSs, or SNSs. Twenty-four hours after transfection, cells were mock-infected or infected with SeV for 16 h followed by the measurement of luciferase activities. Relative luciferase activity (Rel. Luc. Act.) is shown on the left, whereas -fold activation of IFN-␤ promoter (over the corresponding mock groups) by SeV is presented in the middle. Viral protein expression was also detected with WB analyses, and a representative result is shown on the right. B, HEK293 cells were transfected with the HNSs expression plasmid or the vector, and at 24 h post transfection cells were mock-infected or infected with SeV for 12 h followed by the analysis of IFNB1 and RANTES expression with real-time quantitative PCR. Viral protein expression was analyzed with WB. Data are shown as the means Ϯ S.D., n ϭ 3. C, HEK293 cells transfected with the vector plasmid or the plasmids encoding HNSs or SNSs were infected with SFTSV (multiplicity of infection ϭ 0.1) at 24 h post transfection. The virus titers in culture media were measured at the indicated time points post infection by the TCID 50 method.
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of HNSs to impair the innate immunity, we further explored whether HNSs expression can also bolster viral replication. HEK293 cells were transfected with the plasmids encoding HNSs or SNSs or the empty plasmid (vector), and at 24 h post transfection, the transfected cells were infected with SFTSV. At the indicated time points post infection, the titers of the infectious viruses in culture media were measured. As shown in Fig. 2C , the expression of both HNSs and SNSs substantially enhanced the replication of SFTSV, the representative virus of the SFTSV/HRTV-related virus group. These data suggest that HNSs is a functional analogue of SNSs and bolsters viral replication by counteracting the cellular antiviral responses and enhancing viral adaptation on host cells.
HNSs mediated IFN-␤ promoter inhibition by targeting ISRE activation
IFN-␤ promoter contains several distinct regulatory domains to which specific transcription factors can bind (40) . In response to viral infection, transcription factors IRF3 and NF-B are of particular importance for IFN-␤ promoter activation. To identify the transcription factor-mediated signaling targeted by HNSs, we investigated the capacity of HNSs to interfere with the activation of the individual regulatory elements bound by IRF3 or NF-B with DLR assays. Similar to SNSs, HNSs greatly suppressed SeV-induced activation of ISRE, the IRF3-binding element (Fig. 3A) . In contrast, neither of the two NSs proteins exhibited such an inhibitory effect on the NF-B-responsive element (Fig. 3B ). These results suggest that HNSs likely specifically targets the ISRE activation to block IFN/cytokine induction by viral infection. Additionally, as a control, HNP did not noticeably affect the activation of both the transcription factor-responsive elements (Fig. 3, A and B) , which is consistent with the observation that HNP did not interfere with the IFN-␤ promoter activation ( Fig. 2A ).
HNSs suppressed phosphorylation and nuclear translocation of IRF3
During viral infection and in particular the early stage, IRF3 can be phosphorylated by the protein kinase TBK1 and subsequently translocated to nuclei as activated transcription factor (41) (42) (43) (44) (45) . Given the targeting of ISRE activation by HNSs, we next examined the effects of HNSs on the activity of endogenous IRF3. HEK293 cells transfected with the HNSs expression plasmid or the control plasmid (vector) were mock infected or infected with SeV for 6 h followed by the detection of IRF3 phosphorylation with WB analyses. SeV infection led to a notable IRF3 phosphorylation, which, however, was diminished in cells transfected with the HNSs expression plasmid (Fig. 4A ). Subsequently, the nuclear translocation of endogenous IRF3 was also assessed by IFA. HEK293 cells were transfected with the plasmids expressing EGFP-tagged HNSs (EGFP-HNSs) or EGFP alone (as the control), followed by SeV stimulation. As shown in Fig. 4 , B and C, SeV infection remarkably triggered IRF3 translocation to nuclei regardless of EGFP expression. By 
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contrast, the nuclear accumulation of IRF3 was substantially blocked in cells expressing EGFP-tagged HNSs (Fig. 4, B and C) . Collectively, these findings indicate that HNSs prevents IRF3 signaling to repress ISRE activation and, hence, the induction of type I IFNs and other cytokines.
HNSs blocked RLR signaling at the level of the host kinase TBK1
IRF3 is a downstream molecule involved in the antiviral signaling mediated by RLRs that likely play important roles in the cellular recognition of bunyavirus infection (20 -22) . Consider-ing the blockade of IRF3 signaling by HNSs, we tested the effects of HNSs on RLR signaling with DLR assays. The activation of IFN-␤ promoter by the overexpression of RIG-IN (a constitutively active form of RIG-I) or MDA5 was significantly reduced in cells transfected with the HNSs expression plasmid, even at a low transfection dosage (Fig. 5, A and B ), suggesting that HNSs can efficiently block RLR signaling. Furthermore, we addressed the step of the antiviral signaling cascade targeted by HNSs. Signaling proteins downstream of RLRs including the adaptor MAVS, the kinase TBK1, and a constitutively active form of the transcription factor IRF3 (IRF3/5D) were next A, HEK293 cells transfected with the vector plasmid or the HNSs expression plasmid were mock-infected or infected with SeV for 6 h followed by the analyses of IRF3 phosphorylation and protein expression with WB using antibodies against the indicated proteins. ␤-Actin was included as the sample loading control. B, cells were transfected with the plasmids encoding EGFP or N-terminally EGFP-tagged HNSs (EGFP-HNSs). Twenty hours later cells were mock-infected or infected with SeV for 12 h before IFA for visualizing protein localization under confocal microscopy. Endogenous IRF3 (red) was detected with the anti-IRF3 antibody. Nuclei were stained with Hoechst as shown in blue. C, cells treated as in B were scored for the percentages of IRF3 nuclear translocation. For each sample, at least 100 EGFP-positive cells were counted. Data are shown as the means Ϯ S.D., n ϭ 3.
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used to trigger IFN-␤ promoter activation. As shown in the following DLR assays, HNSs inhibited IFN-␤ promoter activation induced by the overexpression of MAVS and TBK1 (Fig. 5 , C and D), suggesting that HNSs acts at the level of TBK1 or further downstream. However, IRF3/5D-induced activation of IFN-␤ promoter was not markedly affected by HNSs (Fig. 5E ), indicating that the NSs protein functions at the upstream of IRF3, collectively, i.e. the level of the kinase TBK1.
Colocalization and interaction of HNSs with TBK1
Because HNSs likely mediates the antiviral signaling blockade at the level of TBK1, we asked whether HNSs targets endogenous TBK1 by protein-protein interactions. First, the subcellular colocalization of HNSs with TBK1 was evaluated by IFA. TBK1 was shown to be greatly colocalized with HNSs in cytoplasm ( Fig. 6A) , indicating the potential HNSs-TBK1 association. Next, the interaction of HNSs with endogenous TBK1 was further examined by S-tag pulldown (S-pulldown) assays. HEK293T cells were transfected with the control plasmid or plasmids encoding S-tagged HNSs (HNSs-S-tag) or HNP (HNP-S-tag) and then used for the S-pulldown assays. As indicated in Fig. 6B , endogenous TBK1 was strongly co-precipitated with HNSs-S-tag but not HNP-S-tag in the S-pulldown products. By contrast, IRF3 was not detected in either HNSs-Stag or HNP-S-tag pulldown products (Fig. 6B) , consistent with the observation that HNSs did not interfere with IRF3/5D-trig-gered activation of IFN-␤ promoter (Fig. 5E ). These observations suggest the specific interaction of HNSs with TBK1.
The scaffold dimerization domain (SDD) of TBK1 was required for TBK1-HNSs interaction
To identify the domain(s) of TBK1 required for TBK1-HNSs interaction, plasmids encoding full-length or C-terminally truncated TBK1 were constructed (Fig. 7A ). Protein interactions between HNSs-S-tag and full-length or truncated TBK1 then were examined by S-pulldown assays. As shown in Fig. 7B , deletion of the C-terminal domain (CTD) did not evidently abate the precipitation of TBK1 in the HNSs-S-tag pulldown product; however, the further removal of the SDD abolished the co-precipitation of TBK1 with HNSs-S-tag ( Fig. 7B) , indicating that the SDD is likely essential for the efficient interaction of the kinase with HNSs.
HNSs obstructed the interaction of TBK1 with the substrate IRF3
Given that HNSs can strongly interact with TBK1 and suppress IRF3 activation, we considered whether the HNSs-TBK1 interaction interferes with the interaction of TBK1 with its substrate IRF3. To validate the consideration, the plasmid expressing an S-tagged TBK1(K38A) mutant (S-tag-TBK1-KA) was cotransfected into HEK293T cells along with increasing amounts of the HA-tagged HNSs (HNSs-HA) expression plas- 
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mid, and at 24 h post transfection, protein interactions were analyzed by S-pulldown assays. TBK1(K38A) is a kinase-inactive form of TBK1 in which the residue Lys-38 was mutated to alanine. As following the phosphorylation of IRF3 by the TBK1-IRF3 interaction, IRF3 needs to rapidly depart from the kinase and relocate into the nucleus for transcriptional modulation, the interaction of IRF3 with the active TBK1 is dynamic, transient, and not readily detected. Thus, we used TBK1(K38A) to assess the TBK1-IRF3 interaction, as did previous studies (46, 47) . As indicated in Fig. 8 , HNSs was largely co-precipitated in the S-pulldown products of TBK1(K38A); this reciprocal pulldown assay further confirmed the HNSs-TBK1 interaction. Meanwhile, HNSs expression indeed inhibited the co-precipitation of endogenous IRF3 with S-tag-TBK1(K38A) in a dosedependent manner. Taken together, these data suggest that the HNSs-TBK1 interaction likely impedes the association of TBK1 with its substrate IRF3 and thus impairs the activation of IRF3 and the induction of interferons and inflammatory cytokines.
Discussion
HRTV can cause severe acute diseases in humans characterized by fever, leukopenia, and thrombocytopenia (1). In fatal cases, patients can develop septic shock, multisystem organ failure and hemorrhage, and viral antigens and RNA can be detected in multiple organ tissues, manifesting the systemic infection (3, 4) . Normal host immune responses are critical for restricting viral systemic infection and pathogenicity. A study on experimental infection of several vertebrate animals with HRTV showed that replicative infections and pathological manifestations could be observed in AG129 (IFN-␣/␤/␥ receptor-deficient) mice but not the immunocompetent animals (48) , which suggests the critical role of IFN system in controlling HRTV infection and pathogenicity. In turn, the virulence of pathogenic viruses is largely determined by their capacity to counteract the host immunity including the IFN response. In this study, we showed that HNSs can robustly antagonize IFN Figure 6 . Colocalization and interaction of HNSs with TBK1. A, analysis of HNSs-TBK1 colocalization. Cells were transfected with the HNSs-S-tag or FLAG-TBK1 expression plasmid supplemented with the corresponding vector plasmids or cotransfected with the plasmids expressing HNSs-S-tag and FLAG-TBK1 followed by fixation for IFA. The localization of HNSs (red) and TBK1 (green) were then visualized with confocal microscopy. Nuclei stained with Hoechst are shown in blue. B, identification of the interaction between HNSs and endogenous TBK1. HEK293T cells were transfected with the vector plasmid or the plasmids encoding S-tagged viral proteins HNSs-S-tag or HNP-S-tag. At 48 h post transfection, protein interactions were analyzed by S-tag pulldown assays. Cell lysates (Lysate input) and S-tag pulldown products (S-pulldown) were then subjected to WB analyses using the indicated antibodies.
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induction in human cells and thus function as a functional SNSs analogue bolstering viral replication. Mechanistically, HNSs strongly interacts with the host kinase TBK1 and blocks TBK1-IRF3 interaction and hence the activation of IRF3, leading to the suppression of IFN/cytokine induction. Therefore, HNSs likely acts as an important virulence factor of HRTV infection. These findings may allow further understanding of HRTV pathogenesis in humans and also provide clues in developing specific immunodeficient animal models (49) . Note that the HNSs function including the potential role as a virulence factor needs to be further explored in the context of the infections of the wild-type virus and mutant viruses with HNSs deletion or mutation. However, as a newly discovered virus, the pathogenicity and transmission risks of HRTV have not been well-assessed, the biosafety facilities required for manipulating infectious HRTV materials have not been specified, and moreover the reverse genetic technique of HRTV has not been established internationally. The solution to these issues will promote the further study of HRTV in future. Antiviral signaling mediated by RLRs was shown to play important roles in the recognition of some bunyaviruses, such as Rift Valley fever virus, Crimean-Congo hemorrhagic fever virus, and SFTSV, and in turn could be countermined by the viruses for immune evasion (20 -22) . Here, we demonstrated that HRTV NSs inhibits RLR signaling at the TBK1 level. TBK1 is a common component of several IFN induction signaling pathways mediated by the major classes of PRRs, including RLRs, toll-like receptors, DEAD-box protein 1 (DDX1), and DNA sensors (18, 50, 51) . Although the PRRs sensing HRTV and their exact roles in restricting HRTV infection and pathogenicity remain to be delineated, considering the targeting of TBK1 by HNSs, HRTV likely has a broad-spectrum capacity of counteracting the antiviral signaling cascades triggered by the multiple PRRs, which remains to be further studied. Additionally, in vivo studies using mutant viruses with engineered HNSs combined with appropriate animal models will further validate the biological significance of HNSs targeting of TBK1 in HRTV infection and pathogenesis.
HRTV is genetically related to but distinct from SFTSV (1). The NSs proteins of HRTV and SFTSV share an identity of ϳ60% in amino acid sequence (1), and as shown in this study, the two proteins have the conservative function that they both antagonize IFN induction by targeting TBK1. However, they also display notable differentiations including their subcellular localization and the further mechanism for the IFN induction antagonism. SNSs can cause the formation of IBs where SNSs locates (35) , whereas HNSs does not noticeably induce any IBlike structures in the cells tested in this work (Fig. 1) . It needs to 
be further investigated whether HNSs can induce any SNSs IB-like structures in other cell types or in vivo in the context of viral infection and other viral protein expression. Our previous studies have demonstrated that SFTSV can utilize SNSs IBs as a virally built "jail" sequestering host proteins including TBK1-IRF3 to block IFN responses (35, 38) ; however, because HNSs does not induce these IB-like structures, HRTV can differ to some extent regarding of the interference with the antiviral signaling at least in the cells we tested. Indeed, although both SNSs and HNSs can interact with TBK1, they still have some delicate differences in antagonizing the TBK1-IRF3 signaling: in SNSs-expressing cells, TBK1 seems to mediate an indirect SNSs-IRF3 interaction by the SNSs-TBK1 and TBK1-IRF3 interactions, and i.e. there is an SNSs-TBK1-IRF3 complex that are sequestrated in viral IBs (35, 37) ; by contrast, the present study showed that HNSs specifically interacts with TBK1 but not IRF3, and moreover HNSs blocks the association of TBK1 with its substrate IRF3 (illustrated in Fig. 9 ). These findings highlight the functional conservativeness of viral suppression of the innate immunity and the mechanistic variability between the viruses. The differentiations of these NSs proteins in the capacity of inducing IB formation and the detailed mechanism of regulating host responses may provide an opportunity to further elucidate the requirement and mechanism of IB formation and the sophisticated virus-host interactions. Additionally, further comparative studies of HRTV, SFTSV, and the related emerging phleboviruses will shed lights on their biology in the evolutionary perspectives.
In summary, this study identified HRTV NSs as a robust antagonist of the host innate immunity. HNSs strongly interacts with the host kinase TBK1 and suppresses the transcription factor IRF3 activation by obstructing the TBK1-IRF3 interaction and signaling, resulting in the blockade of IFN and inflammatory cytokine induction. These findings will benefit the better understanding of viral pathogenesis and the development of antiviral therapeutics.
Experimental procedures
Cells and viruses
HEK293, HepG2, HeLa, and Vero cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% new-born calf serum at 37°C in a 5% CO 2 atmosphere. HEK293T, HUVEC, Huh7.5, and H9c2 cells were cultured in DMEM containing 10% fetal bovine serum (FBS; Gibco). SeV was propagated in 10-day-old embryonated eggs and used as previously described (35) . SFTSV was expanded in Vero or HEK293 cells and manipulated as described previously (35, 38) .
Plasmids
Luciferase reporter plasmids for ISRE, NF-B, and IFN-␤ promoter, control plasmid (pRL-TK), and some RLR signaling protein-expressing plasmids (52) (53) (54) were kindly supplied by Dr. Hong-Bing Shu (Wuhan University, China). Expression plasmids for SNSs, RIG-IN, and IRF3/5D have been described previously (35) . cDNA segments for HNSs (GenBank TM accession number AFP33390) and HNP (GenBank TM accession number AFP33389) were obtained by full-length gene synthesis (Beijing Genomics Institute (BGI), Beijing, China) and cloned into expression vectors with S, HA, or EGFP tag (35, 38) . Expression plasmids for FLAG-tagged full-length, truncated, or mutant TBK1 proteins were constructed by standard molecular biological approaches.
Antibodies
Rabbit antibodies against S-tag (Abcam), human IRF3 or phospho-IRF3 (Ser-396; Santa Cruz Biotechnology, SCBT), human NAK (i.e. TBK1; Cell Signaling Technology), and SeV (MBL) were purchased from the indicated manufacturers. Rabbit anti-SFTSV NP (anti-SNP) antibody used in immunofluorescence assay for virus titration was raised against the SNP protein generated in Escherichia coli. Mouse antibodies against HA tag, FLAG, and ␤-actin were from Beyotime Institute of Biotechnology. Goat anti-mouse IgG-FITC (Proteintech) and anti-rabbit IgG-Cy5 (Abcam) were used as the secondary antibodies in the IFA.
Reporter gene assay
HEK293 cells maintained in 24-well plates were cotransfected with 100 ng of reporter plasmid, 20 ng of control plasmid pRL-TK, and the indicated amounts of plasmids encoding viral proteins per well using Lipofectamine 2000 (Invitrogen). The total amount of transfected plasmids was kept constant for each 
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well through the supplement of the corresponding empty plasmids (vectors). Twenty-four hours post transfection, cells were mock-infected or infected with SeV for 16 h followed by the measurement of luciferase activities with a DLR assay kit (Promega). In data presentation, the firefly luciferase activity was normalized to Renilla luciferase activity to show the relative enzyme activity, and meanwhile the -fold activation over the mock-infected groups was also calculated. In some experiments the IFN-␤ promoter reporter was activated by cotransfection of plasmids expressing RLR signaling proteins including RIG-IN, MDA5, MAVS, TBK1, or IRF3/5D, and in this case, luciferase activities were measured at 36 h post transfection.
Quantitative real-time PCR
The mRNA levels of virus-induced genes were assessed by real-time PCR analyses as previously described (38) . Briefly, total RNA was extracted from HEK293 cells using TRIzol reagent (Life Technologies), and cDNA then was obtained by reverse transcription (RT) with an RT kit (Promega). Quantitative real-time PCR was conducted using an SYBR Green realtime PCR kit (Toyobo) with the primers listed in Table 1 . Relative mRNA levels were calculated by the 2-⌬⌬CT method (55) with the mRNA of GAPDH as an internal control.
Immunofluorescence, confocal microscopy, and virus titration
Transfected or infected cells were fixed with 4% paraformaldehyde in PBS (PFA-PBS) and permeabilized in 0.5% Triton X-100-PBS. After blocking with 2.5% bovine serum albumin (BSA; Biosharp) and 2.5% normal goat serum (Jackson Immu-noResearch) in PBS, cells were incubated with primary antibodies for 1 h at room temperature or overnight at 4°C and stained with secondary antibodies for 1 h at room temperature. For visualization of nuclei, cells were stained with Hoechst 33258 (Beyotime Institute of Biotechnology) for 5 min at room temperature. Images were gained and analyzed with a Nikon Ti confocal microscope and the Volocity software (PerkinElmer Life Sciences) following the manufacturer's instructions.
HEK293 cells transfected with the indicated plasmids were infected by SFTSV with a multiplicity of infection of 0.1 at 24 h post transfection. At the indicated time points post infection, cell culture media were collected, and virus titers were determined by the 50% tissue culture infectious dose (TCID 50 ) method using Vero cells. In the titration, immunofluorescence assay was performed with the anti-SNP antibodies.
Protein interaction analysis
Protein interactions were analyzed with S-tag pulldown assays as previously described (35, 38) . Briefly, cells transfected with the plasmids encoding S-tagged proteins or the corresponding control plasmids were lysed with a lysis buffer (25 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100) containing a mixture protease inhibitor (Roche Applied Science). After centrifugation, supernatants of the cell lysates were incubated with the S-protein agarose slurry (Merck Novagen) at 4°C for 4 h. After extensive washing, the precipitated proteins were extracted from the beads by boiling in 1ϫ SDS sample buffer and then were subjected to SDS-PAGE and WB analyses.
Western blot analysis
Protein samples were first resolved by SDS-PAGE and then transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore). After blocking with 5% BSA in Tris-buffered saline-Tween 20 (TBST), the PVDF membranes were reacted with primary antibodies at 4°C overnight and subsequently with the corresponding secondary antibodies conjugated with horseradish peroxidase (HRP) in 1% BSA-TBST for 1 h at room temperature. Protein band signals on the membranes were detected Figure 9 . TBK1-IRF3 signaling and its blockade by SNSs or HNSs. A, in response to viral infection, TBK1-IRF3 signaling is activated. TBK1 interacts with its substrate IRF3 and phosphorylates IRF3, resulting in the activation of IRF3. Activated IRF3 is subsequently translocated into nuclei and activates ISRE, leading to the expression of IFNs and other cytokines and the establishment of the host antiviral state. B, SNSs interacts with TBK1 and sequesters TBK1 and IRF3 into the IB jail induced by SNSs itself, resulting in the blockade of TBK1-IRF3 signaling. C, HNSs interacts with TBK1 and impedes the TBK1-IRF3 interaction, efficiently blocking the antiviral signaling as well.
Table 1
List of primers for real-time quantitative PCR F, the forward primer; R, the reverse primer.
Primer name
Primer sequence (5 to 3) 
IFNB1-F
